Phase Holographic Imaging initiates CFO succession
Arne Bojesson has since PHI’s IPO in early 2014 been the CFO of PHI. During this time, he has successfully established well-functioning accounting routines, capable of handling PHI’s development. After nearly four years at PHI, Arne Bojesson, age 66, has decided to end his assignment. The company now initiates the recruitment of a successor to Bojesson, who will remain CFO until his position has been securely filled. In conjunction with leaving the Company, Bojesson has divested his holdings of 19 480 shares (0.17%) in PHI.
“It has been a pleasure to work with Arne who with his long experience and seniority has contributed to what PHI is today”, said Peter Egelberg, founder and CEO of PHI.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.